To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.

SA 5336. Mr. WYDEN submitted an amendment intended to be proposed by
him to the concurrent resolution S. Con. Res. 33, setting forth the
congressional budget for the United States Government for fiscal year
2026 and setting forth the appropriate budgetary levels for fiscal
years 2027 through 2035; which was ordered to lie on the table; as
follows:

At the end of title III, add the following:

SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO THE
DUTIES OF THE COMPTROLLER GENERAL OF THE UNITED
STATES.

The Chairman of the Committee on the Budget of the Senate
may revise the allocations of a committee or committees,
aggregates, and other appropriate levels in this resolution,
and make adjustments to the pay-as-you-go ledger, for one or
more bills, joint resolutions reported by the Committee on
Homeland Security and Governmental Affairs of the Senate,
amendments, amendments between the Houses, motions, or
conference reports relating to the duties of the Comptroller
General of the United States, which may include conducting
and publicly releasing a study related to economic
consequences of private or confidential drug pricing
agreements struck by any Federal department, agency, or
office with any pharmaceutical manufacturer, while protecting
proprietary pricing information, by the amounts provided in
such legislation for those purposes, provided that such
legislation would not increase the deficit over the period of
the total of fiscal years 2026 through 2035.
______